Abstract:Aberrant expression and/or activation of the MET receptor tyrosine kinase is characterized by genomic recombination, gene amplification, activating mutation, alternative exon-splicing, increased transcription, and their different combinations. These dysregulations serve as oncogenic determinants contributing to cancerous initiation, progression, malignancy, and stemness. Moreover, integration of the MET pathway into the cellular signaling network as an addiction mechanism for survival has made this receptor an attractive pharmaceutical target for oncological intervention. For the last 20 years, MET-targeting small-molecule kinase inhibitors (SMKIs), conventional therapeutic monoclonal antibodies (TMABs), and antibody-based biotherapeutics such as bispecific antibodies, antibody-drug conjugates (ADC), and dual-targeting ADCs have been under intensive investigation. Outcomes from preclinical studies and clinical trials are mixed with certain successes but also various setbacks. Due to the complex nature of MET dysregulation with multiple facets and underlying mechanisms, mechanism-based validation of MET-targeting therapeutics is crucial for the selection and validation of lead candidates for clinical trials. In this review, we discuss the importance of various types of mechanism-based pharmaceutical models in evaluation of different types of MET-targeting therapeutics. The advantages and disadvantages of these mechanism-based strategies for SMKIs, conventional TMABs, and antibody-based biotherapeutics are analyzed. The demand for establishing new strategies suitable for validating novel biotherapeutics is also discussed. The information summarized should provide a pharmaceutical guideline for selection and validation of MET-targeting therapeutics for clinical application in the future.

Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations

Medicinal Chemistry Strategies for the Development of Bruton’s Tyrosine Kinase Inhibitors Against Resistance

Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.

Targeting Gatekeeper Mutations for Kinase Drug Discovery

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib.

The Prospect of Substrate-Based Kinase Inhibitors to Improve Target Selectivity and Overcome Drug Resistance.

Targeting cancer with small molecule kinase inhibitors

Targeting Solvent-Front Mutations for Kinase Drug Discovery: from Structural Basis to Design Strategies.

FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I

An Interaction Map of Small-Molecule Kinase Inhibitors with Anaplastic Lymphoma Kinase (ALK) Mutants in ALK-positive Non-Small Cell Lung Cancer

Advances in Protein Kinase Drug Discovery Through Targeting Gatekeeper Mutations

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.

Integrated in Silico‐in Vitro Analysis of Systematic Kinase Gatekeeper Mutation Effects on Pan‐kinase Inhibitors in Targeted Liver Cancer Therapy

Dual-target Kinase Drug Design: Current Strategies and Future Directions in Cancer Therapy

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions

Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy

In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from FDA-approved drugs

Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors

Trends in kinase drug discovery: targets, indications and inhibitor design